Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

antifungal

This page shows the latest antifungal news and features for those working in and with pharma, biotech and healthcare.

UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme

UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme

AMR is a major health burden wherein bacteria, fungi, viruses and parasites become resistant to a range of antimicrobial drugs, such as antibiotics, antifungals and antivirals.

Latest news

More from news
Approximately 3 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Basilea has granted an exclusive licence for isavuconazole (an iv and oral antifungal for invasive aspergillosis and mucomycosis) to Asahi Kasei in Japan.

  • Astellas: Ten years young Astellas: Ten years young

    class of OAB treatments to emerge in over 30 years, the antifungal Mycamine (micafungin) and the anti-infective Dificlir - the first new treatment in 50 years for clostridium difficile or c.

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    109. Astellas / Vical. Licence and collaboration. Preclinical antifungal ASP2397. 100.

  • Pharma deals during October 2013 Pharma deals during October 2013

    This proved to be the case with Dow Pharmaceutical Sciences, which had undertaken development work for Anacor on the topical antifungal tavaborole for the treatment of onychomycosis under a 2004 master

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • AstraZeneca’s John Rex joins UK biotech F2G AstraZeneca’s John Rex joins UK biotech F2G

    new role Rex will be tasked with helping move F2G's first-in-class antifungal F901218 through phase II clinical trials. ... John Rex said: “I am delighted to have the opportunity to work more closely with F2G as we take the first orotomide antifungal

  • F2G appoints chief financial officer F2G appoints chief financial officer

    Schmid brings over two decades of financial management experience to the antifungal drug discovery and development company, with particular expertise in mergers and acquisitions, licensing and public and private market transactions.

  • Cidara Therapeutics makes senior appointments Cidara Therapeutics makes senior appointments

    Balkovec has helped bring more than a dozen development candidates into clinical development, including the first approved echinocandin antifungal drug Cancidas (caspofungin), which he is additionally co-inventor of.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Quick links

Infographics

Multimedia